Bank of America Cuts Cencora (NYSE:COR) Price Target to $360.00

Cencora (NYSE:COR) had its price target cut by Bank of America from $380.00 to $360.00 in a research report report published on Monday,Benzinga reports. They currently have a neutral rating on the stock.

Several other analysts have also issued reports on the stock. Robert W. Baird set a $392.00 price target on shares of Cencora in a research report on Tuesday, December 16th. Evercore ISI set a $400.00 target price on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Wells Fargo & Company raised their price target on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. Finally, TD Cowen raised their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $379.50.

Cencora Stock Down 1.6%

Shares of NYSE COR opened at $340.54 on Monday. The stock has a market capitalization of $66.06 billion, a P/E ratio of 42.83, a PEG ratio of 1.65 and a beta of 0.66. Cencora has a one year low of $233.61 and a one year high of $377.54. The firm’s 50 day simple moving average is $350.04 and its two-hundred day simple moving average is $317.68. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period in the previous year, the business posted $3.34 EPS. The business’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, analysts expect that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio is currently 30.19%.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $343.45, for a total value of $1,750,221.20. Following the sale, the chief executive officer owned 68,059 shares in the company, valued at $23,374,863.55. The trade was a 6.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,317 shares of company stock worth $7,009,260 over the last quarter. Corporate insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

A number of institutional investors have recently bought and sold shares of COR. Vanguard Group Inc. grew its holdings in shares of Cencora by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock worth $7,311,810,000 after acquiring an additional 916,506 shares during the period. State Street Corp boosted its position in shares of Cencora by 9.3% during the third quarter. State Street Corp now owns 9,190,316 shares of the company’s stock valued at $2,872,249,000 after purchasing an additional 782,911 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Cencora by 6.3% during the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after purchasing an additional 284,229 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Cencora by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock worth $1,461,965,000 after purchasing an additional 821,098 shares during the period. Finally, Boston Partners raised its holdings in Cencora by 2.0% in the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock worth $1,409,152,000 after purchasing an additional 89,506 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.